#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thyroid cancer metastatic Nephropathy Hypergammaglobulinaemia benign monoclonal Lennox-Gastaut syndrome Hyperoxaluria Neovascular age-related macular degeneration Mitochondrial encephalomyopathy Tuberous sclerosis complex Follicular lymphoma stage II Antiphospholipid syndrome Alagille syndrome Hypochromic anaemia Cystic fibrosis gastrointestinal disease Glycogen storage disease type I NTRK gene fusion overexpression More trials…

    Learn about Rare Diseases

    Andersen-Tawil syndrome – Life with Disease CADASIL – Diagnostics Vascular malformation – Basic Information Optic glioma – Basic Information Acute respiratory distress syndrome – Treatment Synovial sarcoma – Trials in Disease Myelodysplastic syndrome – Diagnostics Pulmonary sarcoidosis – Treatment Waldenstrom’s macroglobulinaemia refractory – Diagnostics Cystic fibrosis lung – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ofatumumab Tofersen RP2 [68GA]GA-NOTA-AE105 Imgn151 Furosemide Sodium Picosulfate R-Azasetron Besilate Delandistrogene Moxeparvovec Caffeine Sar444656 Cobamamide Enzalutamide Posdinemab Glenzocimab Fluvastatin Sodium Human Coagulation Factor X Etoricoxib Perindopril Tert-Butylamine TTX-381 More therapies…

    Learn about Your Condition

    Hyperglycaemia Cerebral amyloid angiopathy Malignant melanoma stage III Left ventricular failure Cholangiosarcoma Cirrhosis alcoholic Colorectal adenocarcinoma Pleomorphic liposarcoma Appendicitis perforated Venous thrombosis Heparin resistance Muscle strain Leukaemia Adenomyosis Lymphoedema More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Kidney transplant rejection

  • Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Frexalimab
    • Tacrolimus
    Austria Belgium Czechia Denmark Finland France +6

  • Study on Imlifidase and Drug Combination for Kidney Transplant in Highly Sensitized Children

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Kidney transplant rejection
    Investigated Drugs:
    • Anti-Human T-Lymphocyte Immunoglobulin From Rabbits
    • Immunglobulin
    • Imlifidase
    Finland France Spain Sweden

  • Evaluation of zirconium-89 crefmirlimab berdoxam PET imaging for monitoring renal allograft rejection in kidney transplant recipients

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Kidney transplant rejection
    Investigated Drugs:
    • Zirconium (89Zr) Crefmirlimab Berdoxam
    The Netherlands

  • A study of allogeneic adipose-derived mesenchymal stem cells for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Kidney transplant rejection
    Investigated Drugs:
    • ALLOGENEIC ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN VITRO EXPANDED
    Denmark

  • Study on Long-Term Safety of Tegoprubart and Tacrolimus for Preventing Kidney Transplant Rejection in Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Kidney transplant rejection
    Investigated Drugs:
    • At-1501
    • Tacrolimus
    France Germany Spain

  • Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Kidney transplant rejection
    Investigated Drugs:
    • Imlifidase
    Austria Belgium Czechia France Germany Italy +4
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!